NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

Start Free »

Altimmune, Inc. ALT | NASDAQ

$2.86 -$0.11 | -3.70%

SIGNAL:

|2026-09-25 |F&G 43 |RSI 35.7

Add to favoritesFavorite

Company Overview:

Market Cap: $530.37M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $2.56 - $6.44

9.3 Year ALT Performance Metrics:

Total Return (with DRIP): -97.9% (-33.83% CAGR)

Total Return (no DRIP): -97.9% (-33.83% CAGR)

Share Price: -97.9% (-33.83% CAGR)

Yield on Cost (with DRIP): 7,864.86%

Total Invested: $10,000

Total Value (with DRIP): $215

Total Return $ (with DRIP): -$9,785

Dividend Increase: N/A (0.00% CAGR)

Dividend Yield (FWD): 366,293.71% ($10,476.00)

ALT 9.3-yr Total Return ($10K invested)

1M 3M 6M YTD 1Y 3Y 5Y 10Y

ALT Share Price

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

ALT Price CAGR:1Y: -24.14%2Y: -31.75%5Y: -24.04%10Y: -33.70%

ALT Dividend Charts

ALT - Dividends

ALT Dividend CAGR:1Y: 0.02%2Y: 0.02%5Y: 0.02%10Y: 0.02%

ALT - Dividend Payout Ratio

ALT Dividend Payout Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Dividend to Free Cash Flow Ratio

ALT Dividend to FCF Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

ALT Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

ALT - Revenue

ALT Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Earnings Per Share (EPS)

ALT EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Net Income

🔓 See the full chart40% off right now · 7-day free trial

ALT Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

ALT EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

ALT Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

ALT Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

ALT Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

ALT Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

ALT Shares Outstanding CAGR:1Y: 127.60%2Y: 61.70%5Y: 35.00%10Y: 95.24%

ALT - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

ALT Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ALT Stock-Based Comp CAGR:1Y: -21.82%2Y: -19.58%5Y: 13.43%10Y: 32.53%

ALT - Expenses

🔓 See the full chart40% off right now · 7-day free trial

ALT Expenses CAGR:1Y: 220.00%2Y: 0.00%5Y: -66.67%10Y: 1.35%

ALT - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

ALT - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ALT - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

ALT - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ALT - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ALT - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

ALT - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

ALT Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

ALT - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ALT Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ALT Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ALT Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ALT Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

ALT - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ALT Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ALT Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

ALT Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

ALT Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

ALT Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

ALT Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ALT Dividends Info:

Annual Dividend: $10476.12

Forward Yield: 366297.9%

Ex-Dividend Date: 2017-01-20

Lifetime Dividends / Share: $1,746.01

ALT Dividend History: Dates, Payments & Yield list

Below is a schedule of all ALT dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield

Ex-Date	Payment Date	Amount	Yield	Forward Yield	Price on Ex-Date
01/20/2017	02/03/2017	$873.010	0%	0%	$-
02/06/2017	11/30/-0001	$873.000	0%	0%	$-

Projected Future Returns & Dividends for ALT

Based on past 9.3-year performance, here are ALT growth metrics:

Share price CAGR of -33.83%
Dividend CAGR of +0%

Using ALT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	ALT (DRIP)	ALT - No DRIP
Current Price	$2.86	$2.86
Start Shares	3,496.50	3,496.50
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	1,000,000.00	3,496.50
Dividends Payment	$252.88	$252.88
Annual Dividends	$3,034,529,546	$10,610,243
Yield on cost	30,345,295.46%	106,102.43%
Share Price	$0.83	$0.83
Total Dividends	$21,124,004,274	$76,901,964
Final Value	$828,432	$76,904,861

Estimated Future Value + Dividends - ALT

NOTE: Above numbers are our estimate based on ALT's Dividend and Price CAGR over past 9.3 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Altimmune, Inc. (ALT) had its IPO on 2017-05-26, and is traded on NASDAQ stock exchange.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

ALT website: https://altimmune.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

DCF Model — ALT

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $2.86

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →